US Patent

US10493028 — Composition and method for vancomycin oral liquid

Formulation · Assigned to CutisPharma Inc · Expires 2035-03-13 · 9y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a stable vancomycin hydrochloride powder for oral liquid formulations and methods for using those formulations to treat certain diseases.

USPTO Abstract

The invention relates to stable vancomycin hydrochloride powder for oral liquid formulations. Also provided herein are methods of using vancomycin oral liquid formulations for the treatment of certain diseases such as Clostridium difficile pseudomembranous colitis and Staphylococcal enterocolitis as well as kits and related products thereof.

Drugs covered by this patent

vancomycin-hydrochloride (VANCOMYCIN HYDROCHLORIDE)

Patent Metadata

Patent number: US10493028
Jurisdiction: US
Classification: Formulation
Expires: 2035-03-13
Drug substance claim: No
Drug product claim: Yes
Assignee: CutisPharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.